Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane N Winter

Showing results (51-60 of 142) with videos related to

Pageof 15
Sort By:
Blood|January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
British Journal of Haematology|April 22, 2008
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin familyAndrew M Evens, Paul T Schumacker, Irene B Helenowski, et al.
Leukemia & Lymphoma|August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomasWilliam B Pearse, Adam M Petrich, Leo I Gordon, et al.
Blood Advances|September 27, 2023
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphomaReem Karmali, Jeremy S Abramson, Deborah M Stephens, et al.
Journal of Hematology & Oncology|June 13, 2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factorsSven de Vos, Andres Forero-Torres, Stephen M Ansell, et al.
Leukemia & Lymphoma|June 22, 2019
Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit statusAmir Behdad, Craig S Boddy, Angela J Fought, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 29, 2009
NCCN task force report: molecular markers in leukemias and lymphomasJerald P Radich, Andrew D Zelenetz, Wing C Chan, et al.
Blood Neoplasia|July 30, 2025
Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408Frederique St-Pierre, Stephen M Broski, Zequn Sun, et al.
British Journal of Haematology|April 14, 2016
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704Soham D Puvvada, Patrick J Stiff, Michael Leblanc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology GroupRalph M Meyer, Mary K Gospodarowicz, Joseph M Connors, et al.
Pageof 15

Showing results (51-60 of 142) with videos related to

Sort By:
Pageof 15
Blood|January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
British Journal of Haematology|April 22, 2008
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin familyAndrew M Evens, Paul T Schumacker, Irene B Helenowski, et al.
Leukemia & Lymphoma|August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomasWilliam B Pearse, Adam M Petrich, Leo I Gordon, et al.
Blood Advances|September 27, 2023
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphomaReem Karmali, Jeremy S Abramson, Deborah M Stephens, et al.
Journal of Hematology & Oncology|June 13, 2014
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factorsSven de Vos, Andres Forero-Torres, Stephen M Ansell, et al.
Leukemia & Lymphoma|June 22, 2019
Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit statusAmir Behdad, Craig S Boddy, Angela J Fought, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 29, 2009
NCCN task force report: molecular markers in leukemias and lymphomasJerald P Radich, Andrew D Zelenetz, Wing C Chan, et al.
Blood Neoplasia|July 30, 2025
Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408Frederique St-Pierre, Stephen M Broski, Zequn Sun, et al.
British Journal of Haematology|April 14, 2016
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704Soham D Puvvada, Patrick J Stiff, Michael Leblanc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology GroupRalph M Meyer, Mary K Gospodarowicz, Joseph M Connors, et al.
Pageof 15